Accelerating Cell Therapy Discovery & Development with Non-Viral Gene Engineering

Traditional virus-based gene engineering systems are limited by low cargo capacity, high manufacturing cost, and long lead times. This whitepaper examines how non-viral transposon-based gene engineering platforms, such as TcBuster™, can be utilized to overcome virus-based platform limitations in cell therapy discovery and development.

In this whitepaper, you’ll learn about:

• The TcBuster transposon mechanism and its pivotal role in ensuring stable protein expression
• Performance outcomes of CAR T cells transposed using TcBuster compared to cells transduced using lentivirus
• Opportunities to de-risk and expedite the discovery and development of cell therapies with non-viral gene engineering
• Potential future contributions of this technology for gene engineering
• Further insights into this novel technology and comparisons to other non-viral systems in a Q&A with our technical experts

This article was transcribed from a webinar demonstrating both T cell and NK cell gene editing using TcBuster, recorded with Cell & Gene Therapy Insights on September 26, 2022.